MET and neoplasm: Treatment with IRCR201 dramatically decreased tumor growth in the c-Met-amplified MKN45 gastric xenograft model, suggesting that it may portray antitumor activity in a broader range of cancer classes with constitutive c-Met activation via genomic amplification or mutations.